Individuals with comorbidities such as hypertension and respiratory system and cardiovascular diseases may have a greater susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a study suggests.
Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) show superiority over other blood pressure (BP)-lowering medications in terms of reducing high-sensitivity C-reactive protein (hs-CRP) and procalcitonin levels in COVID-19 patients with pre-existing hypertension, as shown in a recent study.
The use of Janus kinase (JAK) inhibitors for the treatment of inflammatory bowel diseases (IBDs) and other immune-mediated diseases may increase the risk of herpes zoster infection, reports a recent meta-analysis.
An end-of-treatment (EOT) HBsAg level 40 IU/mL appears to be a useful cutoff value for predicting hepatitis B virus (HBV) infection relapse following cessation of either entecavir or tenofovir disoproxil fumarate (TDF) treatment, as shown in a study. Specifically, low levels of EOT HBsAg and baseline HBV DNA or HBcrAg translate to reduced odds of having relapse.
Upper respiratory (UR) and atypical symptoms are more likely to occur in children with symptomatic pharyngitis and group A Streptococcus (GAS) on throat culture identified as carrier than those who are acutely infected, according to a study.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.